THEMATICAL REVIEW

40 YEARS OF IGF1

IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy

Caterina Mancarella and Katia Scotlandi

Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy

Correspondence should be addressed to K Scotlandi: katia.scotlandi@ior.it

This paper forms part of a special section on 40 Years of IGF1. The guest editors for this section were Derek LeRoith and Emily Gallagher.

Abstract

The insulin-like growth factor (IGF) system has gained substantial interest due to its involvement in regulating cell proliferation, differentiation and survival during anoikis and after conventional and targeted therapies. However, results from clinical trials have been largely disappointing, with only a few but notable exceptions, such as trials targeting sarcomas, especially Ewing sarcoma. This review highlights key studies focusing on IGF signaling in sarcomas, specifically studies underscoring the properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. This review discusses the potential roles of IGF2 mRNA-binding proteins (IGF2BPs), discoidin domain receptors (DDRs) and metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) in regulating the IGF system. Deeper investigation of these novel regulators of the IGF system may help us to further elucidate the spatial and temporal control of the IGF axis, as understanding the control of this axis is essential for future clinical studies.

Introduction

The insulin-like growth factor (IGF) system is involved in many physiological and pathological processes throughout the life span. For example, longitudinal growth; metabolism; longevity and cell development and diseases, such as cancer, obesity, eating disorders and neurodegenerative illnesses, are influenced by the IGF pathway. Thus, IGF signaling must be carefully regulated not only in its magnitude but also in its timing and understanding the mechanisms behind the cell-/tissue-specific regulation of IGF system components is critical for efficiently targeting the system. However, much still needs to be understood. This review highlights key examples of the role of the IGF system in sarcoma pathogenesis and tumor progression and identifies new questions that need to be addressed to provide new fuel for the development of therapeutic strategies.

Key points

- Role of IGF system in sarcomas.
- Lessons learned from clinical studies on sarcomas vs carcinomas.
- Critical issues and novel perspectives.

The IGF system

The IGF system is a very complex system with multiple actors in play. Molecular details of the IGF system have been excellently reviewed by Samani and coworkers.

Key Words

- sarcomas
- IGF system
- targeted therapy
- clinical trials

http://jme.endocrinology-journals.org
https://doi.org/10.1530/JME-17-0250

© 2018 Society for Endocrinology
Published by Bioscientifica Ltd.
Printed in Great Britain

Downloaded from Bioscientifica.com at 04/14/2019 02:17:06AM via free access
(Samani et al. 2007) and Taniguchi and coworkers (Taniguchi et al. 2006). It is beyond the scope of this manuscript to provide a detailed description of the complexity and interactions of this system at the molecular level. However, to inform the reader of the peculiarities of this signaling axis, the most relevant and critical issues are briefly described.

The IGF system is classically described as composed of three ligands (IGF1, IGF2 and insulin), their receptors (IGF1 receptor (IGF1R), mannose 6-phosphate/IGF2 receptor (M6P/IGF2R), insulin receptor (IR) and hybrid IR/IGF1R), at least six IGF-binding proteins (IGFBP1–6), acid labile subunit (ALS) and binding protein proteases. Please refer to Fig. 1 for a schematic diagram of the system.

**Receptors, ligands and IGFBPs**

Insulin and IGFs activate intracellular signaling pathways by binding with high affinity to their cognate receptors (e.g. insulin → IR, IGFs → IGF1R) and with lower affinity to a noncognate receptor (e.g. insulin can also activate IGF1R and IGFs can activate IR). IGF2 also binds IGF2R, which is a mannose 6-phosphate scavenger receptor that does not transmit signals intracellularly. IR has two splice isoforms, IRA, which is highly expressed in fetal tissues and cancer, and IRB, which is mainly present in adult tissues (for a detailed review, please refer to Belfiore et al. 2009). While IRB is a specific receptor for insulin and thus primarily mediates metabolic effects, IRA binds IGF2 and IGF1 (at a lower affinity) and may induce biological effects in response to both IGFs with substantial crosstalk with the IGF1R mitogenic signaling pathway. IGF1R shares 70% homology with IR. Because of the close homology between IR and IGF1R, hybrid receptors can be formed via an interaction between an insulin alpha-beta hemireceptor and an IGF1 alpha-beta hemireceptor in cells expressing both. Hybrid receptors appear to bind IGF1 and IGF2 with a high affinity similar to IGF1R. The interaction between the ligands (IGF1 and IGF2) and IGF1R, IR or the hybrid receptors results in trans-autophosphorylation of the intracellular portion of the receptors and the subsequent recruitment of downstream signaling adaptor proteins, IR substrate (IRS) 1–6 and Src homology 2 domain-containing transforming protein (Shc), to the cell membrane (for reviews see Butler et al. 1998, Samani & Brodt 2001). The subsequent phosphorylation of these proteins induces the activation of phosphoinositide 3-kinase (PI3K) (Giorgetti et al. 1993) and mitogen-activated protein kinases (MAPK) pathways (Grey et al. 2003), resulting in the stimulation of cellular proliferation and cell motility and the inhibition of apoptosis. Although the IGF system receptors have many similarities, the biological response elicited by each IGF system receptor can vary depending on (1) the ligands involved, (2) the expression of a specific IR isoform and (3) the recruitment of certain docking proteins and intracellular mediators, and the dynamics and regulation involved are still not completely understood (Frasca et al. 2008).

These complex functional interconnections between receptors and ligands imply that whenever the effects of IGF1R, IR or both are studied, the prevalent types and
expression levels of the ligand(s) in that specific cellular context should also be examined. When exploring IGF1R and IR signaling in cancer, considerable attention was given to abnormal signaling after the interactions between IGFs and their receptor/s. However, the mechanism by which IGFs and/or insulin in plasma are regulated prior to interacting with their receptor/s is as important as the intracellular signaling pathway. Many epidemiological studies reported that individuals with IGF1 levels at the upper end of the normal range have an increased risk of developing certain cancers, e.g. prostate, breast and colon cancers (Chan et al. 1998, Endogenous et al. 2010, Rinaldi et al. 2010). Conversely, individuals with Laron’s syndrome, which is characterized by very low IGF1 levels, appear to be protected from the development of cancer (Shevah & Laron 2007); moreover, reducing circulating IGF1 levels by caloric restriction decreases tumor growth (Brandhorst et al. 2015).

**Relevant checkpoints in regulating the IGF system**

The level of free IGFs is affected by the rate of IGF production, clearance and binding to IGFBPs. IGFs circulate in large part bound to one of the six IGFBPs, mainly IGFBP3 and IGFBP5, fractions of which further form ternary complexes with ALS. This results in an increase in IGFs half-life (Baxter 2000). The IGFBPs circulate in molar excess of IGFs and have ligand affinities at the same order of magnitude as the ligands have for the IGF1R (Clemmons 1998). Most IGFBPs compete with IGFs for binding to respective receptors and antagonize IGF function, while some (e.g., IGFBP2) appear to amplify IGF signaling (Grimberg & Cohen 2000). Mohan and Baylink provided a detailed review on IGF-binding proteins that regulate the biological accessibility and activity of IGFs (Mohan & Baylink 2002). In addition to IGF-dependent mechanisms of actions, IGFBPs bind non-IGF ligands in the extracellular space, cell membrane, cytoplasm and nucleus, thereby modulating cell proliferation, survival and migration in an IGF-independent manner (Granata et al. 2004, Han et al. 2011).

Alterations in IGF-mediated functions also involve modulating IGF2R, which lacks transketolase activity, does not transmit signals, and may serve as a scavenger receptor for IGF2. Loss-of-functional IGF2R, a condition largely observed in tumors, likely facilitates an enhanced interaction between IGF2 and IGF1R (Devi et al. 1999, Martin-Kleiner & Gall Troselj 2010). In addition, alterations in phosphatase and tensin homologue (PTEN), which is a tumor suppressor and lipid phosphatase (Zhao et al. 2004), and altered expression of adaptor proteins IRSs (Chang et al. 2002) and Shc (Ursini-Siegel et al. 2008) are also involved in IGF signaling regulation.

Finally, recent discoveries on post-transcriptional and proteolytic regulation of IGF activity have provided novel insights into the intricate control of the IGF system.

To date, no reports have described mutations in any genes encoding IGFs, receptors or the six IGFBPs; however, a notable exception is osteosarcoma, where recurrent mutations in genes mediating IGF signaling via IGF1R (focal amplification of IGF1R and IGF1; frameshift indels in recessive cancer genes, IGF2R and IGFBP5) have been recently described in 7% of tumors (Behjati et al. 2017). More commonly, reports have described the expression of IGF system players, to a large extent, at the transcriptional and post-transcriptional levels with functions that can be influenced by genetic and epigenetic changes. Interestingly, mutations in metalloproteinase pregnancy-associated plasma protein-A2 (PAPP-A2), one of the proteases believed to increase the local bioavailability of IGFs by cleaving inhibitory IGFBPs (Conover 2012), were recently discovered in patients with growth failure (Dauber et al. 2016). The impact of these mutations in cancer, as well as the expression of stanniocalcin 1 and 2 (STC1 and STC2), which are potent proteinase inhibitors of PAPP-A (Jepsen et al. 2015, Kloeverpris et al. 2015), have been poorly explored in relation to the IGF system; however, these alterations may significantly affect the role of PAPP-A in certain malignancies. Targeting the proteolytic activity of PAPP-A is relevant to preventing cancer growth and metastases (Becker et al. 2015), thus sustaining further investigations.

Beyond their canonical role in digesting extracellular matrix proteins, matrix metalloproteinases (MMPs) have a specific role in cleaving IGFBPs, thus leading to IGF liberation. In epithelial cells, IGFBP5 is cleaved by MMP7, which consequently releases IGF2 and promotes a proliferative cellular response (Hemers et al. 2005). In prostate cancer cells, MMP9 was described as having a proteolytic effect on IGFBP3 (Manes et al. 1999). In this perspective, targeting MMPs was postulated as a novel therapeutic strategy against cancer (Egeblad & Werb 2002).

Another interesting regulator of the IGF system are the IGF2 mRNA-binding proteins, a family of mRNA-binding proteins (RBPs) consisting of three paralogs (IGF2BP1, 2 and 3) involved in RNA localization, translation and stability (Christiansen et al. 2009). These RBPs are oncofetal proteins that are highly expressed during both human and mouse embryogenesis. Although
these RBPs may affect stability and translation of many transcripts, Nielsen and colleagues demonstrated that IGF2BPs specifically drive physiological regulation of IGF2 translation at both a temporal and spatial level during late mammalian development (Nielsen et al. 1999). With the notable exception of IGF2BP2, IGF2BP1 and IGF2BP3 are expressed at low levels in adult tissues and are re-expressed in malignancies. Of note, IGF2BP3 has been described as playing a specific role in regulating IGF2 and IGF1R mRNA expression that leads to increased IGF signaling in different tumor types (Hafner et al. 2010, Fawzy et al. 2016, Panebianco et al. 2017).

Moreover, previous studies described novel relevant interactions between IGF1R or IR and discoidin domain receptor 1 (DDR1). DDR1 belongs to a subfamily of membrane tyrosine kinase receptors, including five DDR1 isoforms and DDR2, and these DDRs bind to and are activated by different types of collagen (for a review, consider (Valiathan et al. 2012)). DDRs are characterized by an extracellular discoidin domain, a long juxtamembrane region and 13–15 tyrosine residues in their cytoplasmic domain that serve as binding sites for SH2 and phosphotyrosine-binding (PTB) domain-containing molecules for signal transduction. Interestingly, DDR1 constitutively associates with IGF1R, and this interaction is enhanced after IGF stimulation and leads to an increase in IGF1R expression levels as well as signaling and biological effects. Importantly, silencing DDR1 was found to decrease the IGF1R biological response after IGF stimulation, and the absence of IGF1R was reported to impair collagen-dependent DDR1 activation, thus further indicating the close crosstalk between the two molecules (Malaguarnera et al. 2015). Similarly, in response to insulin or IGF2, DDR1 co-localizes with IRA and influences its biological actions. Indeed, DDR1 knockdown inhibits IRA signaling, as well as IRA-elicited proliferation and migration after ligand stimulation. Importantly, DDR1 regulates IR expression levels through both transcriptional and post-transcriptional mechanisms (Morcavallo et al. 2011, Vella et al. 2017).

Please refer to Fig. 2 for a schematic representation of the IGF system and all relevant regulators controlling this axis.

Despite this level of complexity, IGF1R signaling has been the only focus of previous studies, and selective IGF1R inhibitors have been the first and, unfortunately, the only therapy to progress from bench to bedside. Considering these intricacies of the IGF system, it is now clear that the current understanding of this system is a gross oversimplification of the real interconnections that may alter IGF-mediated signals.

Historically, IGF1R was chosen as the therapeutic target because of the following: (i) the first evidence by Sell and colleagues demonstrated that IGF1R is quasi-obligatory for cell transformation (Sell et al. 1993) and (ii) multiple preclinical studies demonstrated that downregulation or inhibition of IGF1R in malignant cells induces cell death, inhibits tumorigenesis and metastasis and increases chemosensitivity to conventional and targeted drugs.

It was therefore not surprising that targeting IGF1R became popular with pharmaceutical companies. Monoclonal antibodies and tyrosine kinase inhibitors were designed to specifically target IGF1R, and several phase I to III clinical trials were conducted. From these studies, we obtained some important indications: (1) anti-IGF1R drugs have modest toxic effects and (2) anti-IGF1R drugs show limited effectiveness. Because of this disappointing evidence, the development of anti-IGF1R agents was largely abandoned. However, sarcoma studies found a few extraordinary results that deserve deeper analysis and follow-up investigations.

**IGF system in sarcomas**

The IGF system has been demonstrated to be clearly involved in the pathogenesis and progression of sarcomas that tend to occur in younger patients, such as osteosarcoma, Ewing sarcoma and rhabdomyosarcoma. Although there are no direct data describing a relationship between IGF levels and sarcoma risk, the peak incidence of primary bone sarcoma (osteosarcoma and Ewing sarcoma) correlates with increased levels of IGF ligands in puberty. Growth hormone (GH) and IGFs are important regulators of growth and development in normal bone and contribute to approximately 50% of basal bone cell proliferation (for reviews see Cannata et al. 2010, Al-Kharobi et al. 2014). IGFs also promote differentiation of myoblastic or osteoblastic tissues into muscle and bone (Schmid et al. 1983), and glucose uptake favors osteoblast differentiation by suppressing AMP-activated protein kinase (AMPK)-dependent proteasomal degradation of Runx2 (Wei et al. 2015), a master determinant of osteoblast differentiation. Thus, it is conceivable that defects in molecules involved in IGF signaling may play a role in the formation of musculoskeletal tumors.

Previous studies described the expression of IGFs and IGF1R in tumor cells from primary high-grade osteosarcoma, which is an aggressive tumor derived from...
osteoblastic precursors and found that IGF and IGF1R expression levels are functionally related to malignant growth and invasion in several preclinical models (Kappel et al. 1994, Benini et al. 1999, MacEwen et al. 2004, Duan et al. 2009, Kuijjer et al. 2013, Cao et al. 2014). Loss of IGFBPs and IGFBP-related proteins (IGFBP-rPs),
which are generally believed to inhibit the effects of IGFs, has also been found in osteosarcoma but not normal bone cells (Yang et al. 2016). Of note, during normal osteoblastic terminal differentiation, the expression of IGFs progressively increased, while the expression of IGF1R progressively decreased (Viereck et al. 2007), suggesting that upregulation of the receptor, rather than the ligands, is the aberrant condition in osteosarcoma. Accordingly, using fluorescence in situ hybridization, Behjati and coworkers (Behjati et al. 2017) found high-level amplification of IGF1R in 14% of cases, while mutations in genes mediating signaling via IGF1R were found in 7% of patients. Polymorphisms of IGF2R are also significantly associated with an increased risk for osteosarcoma (Savage et al. 2007), likely affecting interactions between ligands and IGF1R and leading to its increased activity. In addition, a multistage genome-wide association study of the incidence of metastasis at diagnosis in 935 osteosarcoma patients identified a SNP rs7034162 in the nuclear factor 1 B-type (NFIB) gene that was significantly associated with metastasis in European, African and Brazilian patients (Mirabello et al. 2015). This study therefore identified NFIB, which encodes a transcription factor that regulates IGFBP5 expression in human osteoblasts (Perez-Casellas et al. 2009), as an osteosarcoma metastasis susceptibility gene. Interestingly, IGFBP5, the most abundant IGFBP stored in bone, inhibits tumor growth and metastasis of human osteosarcoma cells (Su et al. 2011, Luther et al. 2013).

The IGF1R pathway is a major autocrine loop that plays a key role in the pathogenesis and malignant behavior of Ewing sarcoma (Scotlandi et al. 1996, 1998, 2002, 2005, Scotlandi & Picci 2008). EWS-FLI1, a fusion gene and genetic hallmark of Ewing sarcoma, was found to have transforming properties only in the presence of IGF1R (Toretsky et al. 1997), and more recently, this fusion product was found to directly affect IGF1R signaling by either downregulating IGFBP3 (Prieur et al. 2004) or increasing IGF1 promoter activation (Herrero-Martin et al. 2009, Amaral et al. 2015). Robust upregulation of IGF1 was also described in mesenchymal progenitor cells transformed by EWS-FLI1 (Riggi et al. 2005).

Data showing that a PAX3/-FOXOA1 fusion protein, which is a genetic hallmark of alveolar rhabdomyosarcoma, activates the IGF1R gene promoter and increases expression of IGF1R are compelling (Ayalon et al. 2001). In addition, high levels of IGF2 in rhabdomyosarcoma were determined in previous studies describing loss of imprinting (Zhan et al. 1994, Wang et al. 1998), and IGF2 was found to cooperate with PAX3-FKHR in tumor oncogenesis (Wang et al. 1998, de Souza et al. 2012). Patients with stage III rhabdomyosarcoma can be categorized into patients who will proceed either poorly or well by considering high or low levels of Akt phosphorylation (i.e., higher or lower tonic IGF1R signaling (Crist et al. 2001, Petricoin et al. 2007)). As such, these findings further support the importance of IGF1R as a potential therapeutic modality in alveolar rhabdomyosarcoma.

Similarly, IGF1R has been found to be highly expressed in desmoplastic small cell tumors due to a direct activation of the IGF1R promoter by EWS-WT1, a genetic hallmark of this tumor. Interestingly, a truncated version of the fusion protein EWS-WT1 that has alternative mechanisms of action still stimulated IGF1R expression such that the receptor upregulation remained a consistent consequence of the genetic aberration in the fusion protein (Karnieli et al. 1996, Werner et al. 2007). In synovial sarcoma, elevated expression of IGF2 is induced by synovial sarcoma oncoprotein SYTSSX and appears to be required for tumor formation in vivo (Sun et al. 2006).

High expression of IGF2 was also observed in gastrointestinal stromal tumor (GIST) (Steigen et al. 2009). In addition, approximately 7% of GISTs without tyrosine-protein kinase KIT or platelet-derived growth factor receptor alpha (PDGFRα) mutations were found to express IGF1R in excess of that seen in KIT or PDGFRα mutant GIST, and cell death was observed after treating these cell lines with IGF1R inhibitors (Agaram et al. 2008, Tarn et al. 2008).

The utility of IGF1R inhibitors (monoclonal antibodies and small-molecule tyrosine kinase inhibitors) was demonstrated in preclinical models against Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, synovial sarcoma cells and desmoplastic round cell tumor, and these inhibitors were convincingly shown to block cancer cell proliferation, survival and anchorage-independent growth in vitro; to block tumorigenesis, tumor invasion and metastasis and to sensitize cancer cells to chemotherapy and radiotherapy (Kalebic et al. 1994, Scotlandi et al. 1998, 2005, Benini et al. 2001, Martins et al. 2006, Manara et al. 2007, Kolb & Gorlick 2009).

Together, these findings strongly support the concept of pursuing IGF1R as a target for therapeutic intervention in these sarcomas.

Results from clinical trials

Numerous therapeutic agents targeting the IGF1R pathway have been developed. These agents include monoclonal
antibodies (mAb) that specifically inhibit IGF1R (dalotuzumab, figitumumab, cixutumumab, ganitumab, R1507 and AVE1642); several IGF1R/IR tyrosine kinase inhibitors (TKIs), including a dual inhibitor of IGF1R and IR OSI-906 (linsitinib) (Mulvihill et al. 2009) and, more recently, monoclonal antibodies against IGF1 and IGF2 (MEDI-573 and BI 836845) (Gao et al. 2011, Friedbichler et al. 2014).

Different anti-IGF1R mAbs have been tested in early clinical trials involving patients with carcinomas and sarcomas. In sharp contrast with the effects of IGF1R inhibitor monotherapy in a subset of patients with sarcoma, largely unimpressive or even pessimistic results were obtained from studies of carcinoma (Qu et al. 2017). Table 1 summarizes the main clinical results obtained from sarcoma studies.

**Table 1** Most important clinical studies involving anti-IGF1R agents in sarcomas.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Phase</th>
<th>Tumor types</th>
<th>Disease control</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>R1507</td>
<td>I</td>
<td>9 pts with multiple Sarcoma subtypes; 9 pts with Ewing sarcoma</td>
<td>Ewing sarcoma: 2 PR; 2 SD Leiomiosarcoma: 1 SD</td>
<td>Kurzrock et al. (2010)</td>
</tr>
<tr>
<td>Figitumumab (CP-751,871)</td>
<td>I</td>
<td>13 pts with multiple sarcoma subtypes; 16 pts with Ewing sarcoma</td>
<td>Ewing sarcoma: 1 CR; 1 PR; 6 SD Synovial sarcoma: 1 SD Fibrosarcoma: 1SD</td>
<td>Olmos et al. (2010)</td>
</tr>
<tr>
<td>Figitumumab (CP-751,871)</td>
<td>I</td>
<td>16 pts with Ewing sarcoma; 11 with osteosarcoma; 4 with other sarcomas</td>
<td>15 PR; 25 SD Ewing sarcoma: 1 PR; 8 SD DSRCT: 1 PR; 13 SD</td>
<td>Juergens et al. (2011)</td>
</tr>
<tr>
<td>Ganitumab</td>
<td>II</td>
<td>106 pts with Ewing sarcoma</td>
<td>Ewing sarcoma: 1 PR; 8 SD DSRCT: 1 PR; 13 SD</td>
<td>Tap et al. (2012)</td>
</tr>
<tr>
<td>Cixutumumab (IMC-A12)</td>
<td>II</td>
<td>22 pts with Ewing sarcoma</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td>Schoffski et al. (2013)</td>
</tr>
<tr>
<td>R1507</td>
<td>II</td>
<td>115 pts with Ewing sarcoma</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td>Pappo et al. (2011)</td>
</tr>
<tr>
<td>R1507</td>
<td>II</td>
<td>38 pts with osteosarcoma</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td>Pappo et al. (2014)</td>
</tr>
<tr>
<td>R1507</td>
<td>II</td>
<td>36 pts with rhabdomyosarcoma</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td></td>
</tr>
<tr>
<td>Robatumumab</td>
<td>II</td>
<td>23 pts with synovial sarcoma</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td></td>
</tr>
<tr>
<td>Cixutumumab (IMC-A12)</td>
<td>II</td>
<td>66 pts with other sarcomas</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td></td>
</tr>
<tr>
<td>Cixutumumab (IMC-A12)</td>
<td>II</td>
<td>144 pts with Osteosarcoma or Ewing sarcoma metastasis</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td></td>
</tr>
<tr>
<td>Cixutumumab (IMC-A12)</td>
<td>II</td>
<td>144 pts with Osteosarcoma or Ewing sarcoma metastasis</td>
<td>1 CR; 10 PR; 18 SD Osteosarcoma: 2 PR; 10 SD</td>
<td></td>
</tr>
<tr>
<td>Cixutumumab (IMC-A12)</td>
<td>I</td>
<td>17 pts with Ewing’s sarcoma</td>
<td>Ewing sarcoma: 2 CR; 5 PR DSRCT: 1 PR; 1 SD</td>
<td>Naing et al. (2012)</td>
</tr>
<tr>
<td>Figitumumab (CP-751,871)</td>
<td>I</td>
<td>3 pts with desmoplastic small round cell tumors</td>
<td>Solitary fibrous tumor: 1 PR; various: 14 DS</td>
<td>Quek et al. (2011)</td>
</tr>
<tr>
<td>Cixutumumab (IMC-A12)</td>
<td>II</td>
<td>388 pts with bone and soft tissue sarcomas (61 pts with Ewing sarcoma)</td>
<td>Osteosarcoma: 2 PR; 10 SD DSRCT: 1 PR; 1 SD</td>
<td></td>
</tr>
<tr>
<td>Cixutumumab + doxorubicin</td>
<td>I</td>
<td>Pts with multiple soft tissue sarcoma subtypes</td>
<td>Various: 5/26 PR 14/26 SD</td>
<td>Chugh et al. (2015)</td>
</tr>
</tbody>
</table>

CR, complete response; PR, partial response; pts, patients; SD, stable disease.
Garofalo et al. 2016). In osteosarcoma, the lack of responses may have been due to the redundancy of autocrine loops that characterize this tumor (Benini et al. 1999), which likely prevented any efficacy of inhibitors specifically targeting single pathways. Of note, some evidence of efficacy was observed in osteosarcoma when multikinase inhibitor sorafenib was used (Grignani et al. 2015) in combination with everolimus, an mTOR inhibitor.

The combination of mTOR and IGF1R inhibition has been tested in patients with several types of advanced sarcomas and has occasionally yielded responses or prolonged disease stability in patients with metastatic solitary fibrous tumor; Ewing sarcoma; high-grade spindle cell sarcoma; osteosarcoma and, among soft tissue sarcoma, leiomyosarcoma (Quek et al. 2011, Naing et al. 2012, Schoffski et al. 2013). Considering the role of IGF1R in mediating resistance to chemotherapy, combinations of anti-IGF1R antibodies with cytotoxic agents, such as docetaxel, gemcitabine, erlotinib and doxorubicin, have also been tested (Macaulay et al. 2013, Chugh et al. 2015) and have yielded durable responses in a few patients with leiomyosarcoma. Toxicities observed were of a similar character and severity as those reported for each single agent, confirming the lack of serious safety concerns for agents targeting IGF1R even when used in combination. Moreover, the most common side effects, hyperglycemia and hyperlipidemia, are mostly tolerable and manageable. Combining anti-IGF1R mAbs with metformin, an anti-diabetic drug with anticancer efficacy (Martin & Marais 2012), may be a good choice to control hyperglycemia.

The major problems of IGF1R inhibition are not side effects but, rather, the rapid development of resistance with short-lived, clinical responses. Resistance to agents specifically targeting IGF1R is likely intrinsically associated with the complex, redundant interactions that characterize the IGF system. Garofalo and coworkers (Garofalo et al. 2011, 2012) and Beltran and coworkers (Beltran et al. 2011) proposed a compensatory signaling mediated by IGF2 through the IR that was not downregulated by anti-IGF1R antibodies. Alterations in downstream pathways, such as PI3K/AKT axis or RAS/MAPK, modulation in IGFBPs expression or activation of alternative signaling have also been considered as potential mechanisms associated with resistance to anti-IGF1R agents (Cao et al. 2008, Haluska et al. 2008, Huang et al. 2010, Kang et al. 2014). Overexpression of epidermal growth factor receptor (EGFR) signaling was particularly suggested in adaptive resistance to IGF1R inhibition and vice versa (for a review see Jones et al. 2006), supporting the rationale for combining IGF1R and EGFR inhibitors, even in sarcomas. Particularly, the study performed by Huang et al. demonstrated the synergistic or additive effects given by the IGF1R/EGFR combined treatment in rhabdomyosarcoma cells (Huang et al. 2009). However, clinical trials have been disappointing. A phase I study in patients with solid tumors, including sarcomas, indicated that the human anti-IGF1R antibody AVE1642 was tolerable when combined with gemcitabine and erlotinib and achieved durable disease control in 44% of patients (Macaulay et al. 2013). However, a randomized phase 2 trial of erlotinib with or without the anti-IGF1R mAb R1507 failed to show difference in non-small-cell lung cancer and adding the dual IGF1R/IR linsitinib to erlotinib resulted in inferior outcomes compared with erlotinib alone (Leighl et al. 2017). Negative results were also obtained for colorectal cancer (Van Cutsem et al. 2014) and pancreatic cancer (Philip et al. 2014).

The appreciation of IR-mediated signaling as a potential mechanism of resistance to agents specifically directed against IGF1R has led to studies testing linsitinib, which simultaneously inhibits IGF1R and IR (Mulvihill et al. 2009), as well as antibodies directed against the IGF1 and IGF2 ligands (Gao et al. 2011) in patients with advanced solid tumors. Linsitinib has been evaluated as a single agent (Fassnacht et al. 2015, Jones et al. 2015, Puzanov et al. 2015) or, more recently, in combinations with paclitaxel or erlotinib in patients with metastatic carcinomas (Bendell et al. 2015, Ciuleanu et al. 2017, Leighl et al. 2017). Only very limited effects were reported. No data are available for sarcomas, although recent preclinical studies have indicated combined inhibition of IR and KIT as a potential therapeutic strategy in imatinib-resistant GISTs (Chen et al. 2017).

MEDI-573 has also been tested in patients with advanced, heavily pretreated solid tumors, and these patients exhibited a disease stabilization rate of 30% with no observed PRs or CRs (Haluska et al. 2014). A second phase I study of a Japanese population confirmed that MEDI-573 was well tolerated at the doses investigated but with limited efficacy (Iguchi et al. 2015).

Overall, clinical trials indicated that some treatment combinations induce disease stabilization in 20–40% of patients and clinical responses in a small percentage of patients with sarcoma, especially Ewing sarcoma.

Most studies noted the need of predictive biomarkers for identifying patients who would likely respond to this therapeutic strategy. To date, tumor expression of IGF1R (Schwartz et al. 2013) and its pathway components (Naing et al. 2011), serum IGF levels (Juergens et al. 2011,
Pappo et al. 2011, Macaulay et al. 2013), assessment of alternate pathway activation and attempts at identifying specific molecular signatures associated with IGF1R pathway dependence have been analyzed with varying levels of success. Exclusive nuclear localization of IGF1R was associated with responses to various IGF1R Abs in patients with sarcoma, suggesting that IGF1R nuclear translocation could also be a biomarker of IGF pathway activation (Asmane et al. 2012). However, despite these findings, the interpretation of the heterogeneous responses in terms of efficacy and tolerability to therapies targeting IGF1R inhibitors is still far from being fully elucidated.

**Critical issues**

1. Scheduling and identification of predictive biomarkers remain to be resolved.
2. The sample size of clinical studies was too small. Phase 3 clinical trials were only a small proportion of the enrolled studies, and the overall population was not large enough to obtain relevant data.
3. An oversimplified vision of IGF signaling has very likely limited a full appreciation of the pathway, leading to a dismal scenario for the development of therapeutic agents in cancer.

**New perspectives**

1. Several lines of evidence provide a rationale for combining IGF signaling inhibitors and immune therapies. The contribution of the IGF axis in regulating immune function was first highlighted in a series of studies reporting that downregulating IGF1 or IGF1R enhanced the immunogenicity of glioblastoma models in rats (Resnicoff et al. 1994) as well as in a small clinical study on astrocytoma (Andrews et al. 2001). IGF1 has also been implicated in the expression of immunosuppressive cytokines, including interleukin-10 (Kooijman & Coppins 2004), and the induction of the M2 macrophage phenotype (Barrett et al. 2015). A defect in IGF1/Akt signaling has been associated with a decreased capacity to induce the M2 state and an increased responsiveness to interferon gamma (IFNγ). This observation may be particularly relevant for osteosarcoma, in which tumor-associated macrophages (TAMs) were found to correlate with reduced metastasis and improved survival (Buddingh et al. 2011). Liposome-encapsulated muramyl tripeptide (L-MTP-PE), which enhances the potential antitumor activity of macrophages, has been introduced in the treatment of osteosarcoma patients (Meyers & Chou 2014), and IL-10-polarized M2-like macrophages were able to reduce osteosarcoma cell growth in the presence of the anti-EGFR cetuximab in a mechanism involving antibody-dependent tumor cell phagocytosis (Pahl et al. 2014). In addition, inhibition of IGF1R promotes the expansion of activated human NK cells, which maintain antitumor responses against Ewing sarcoma (Jamitzky et al. 2015), indicating that combining adoptive NK cell transfer with IGF1R targeting may be an efficient strategy to eliminate minimal residual disease after conventional therapy.

2. Future clinical trial should select patients by specific biomarkers to increase efficacy. IGF1R antibodies were well tolerated in some trials, whereas, in others, they caused more severe side effects. The diverse effects and tolerance of IGF1R mAbs in different trials refer to many possible mechanisms, most of which were unclear. Understanding the mechanisms of these mAbs requires a better evaluation of the crosstalk between IGF1R and other signaling components (Lamhamedi-Cherradi et al. 2016) as well as consideration of players that have thus far been poorly considered in terms of IGF system regulation. These players may include the following:

a. Evaluation of IGF2BP family members. Correlative and functional studies have extensively described the elevated expression of IGF2BPs in human cancer but not in adult normal tissues, indicating an oncogenic role in different tumor types, including leukemia, carcinoma and bone and soft tissue tumors. In particular, high IGF2BP3 expression was reported in leiomyosarcoma (Cornejo et al. 2012), osteosarcoma (Do et al. 2008), chondrosarcoma (Shooshtarizadeh et al. 2016) and Ewing sarcoma (Mancarella et al. 2016). Due to its ability to sustain IGF2 expression with a consequent activation of IGF1R signaling pathway, IGF2BP3 may represent an intriguing biomarker to predict the therapeutic response to IGF1R inhibition. Accordingly, in vitro and in vivo evidence showed that sensitivity to the dual inhibitor linsitinib is higher in cancer cells overexpressing IGF2BP3 than in cells with low IGF2BP3 expression (Panebianco et al. 2017). In addition, IGF2BPs are envisioned as potential novel therapeutic targets, but so far, limited data are available regarding the direct inhibition of these proteins. In vitro evidence showed that treatment
with an isocorydine derivative (d-ICD) inhibited IGF2BP3 expression and reduced the growth of hepatocellular carcinoma cells (Li et al. 2015). Beyond the possibility to directly block IGF2BP3 expression, the role of IGF3BP3 as a vaccine target was postulated. The study from Tomita and coworkers indicated that immunogenic peptides derived from IGF2BP3 can induce tumor-reactive and human leukocyte antigen (HLA)-A2 (A*02:01)-restricted cytotoxic T lymphocytes (CTL) in lung cancer patients (Tomita et al. 2011), thus opening potential novel therapeutic avenues.

b. Evaluation of the metalloprotease PAPP-A. For tumors expressing high levels of PAPP-A, benefits of inhibiting its proteolytic activity have been described. In Mikkelsen et al. (2014) developed an inhibitory monoclonal antibody targeting a unique substrate-binding exosite of PAPP-A (mAb-PA). This antibody was shown to inhibit the proteolytic cleavage of IGFBP4, which blocked the intracellular signaling of IGF1R in vitro and in vivo (Mikkelsen et al. 2014). Afterwards, the efficacy of the mAb-PA was tested in primary patient ovarian xenografts showing that the efficacy of mAb-PA was strongly dependent on PAPP-A expression levels. Addition of mAb-PA to standard chemotherapy improved tumor regression (Becker et al. 2015). A very interesting aspect of this therapeutic approach is that the mAb-PA reduces the bioavailability of IGF1 and IGF2 but not of insulin, sparing any side effects due to metabolic dysregulation. PAPP-A has been described to be overexpressed in Ewing sarcoma, and TCR transgenic T cells directed against PAPP-A were found to reduce tumor growth in mice (Kirschner et al. 2017), thus providing novel possibilities in therapeutic approaches. Considering that even minor modifications in the balance of active and inhibited PAPP-A may have a large effect on the local or systemic generation of bioactive IGF1, more detailed studies on how the expression of PAPP-A and its regulators stanniocalcin 1 and 2 (STC1 and STC2) are controlled are strongly encouraged. STCs are involved in diverse physiological processes, including osteoblast differentiation, adipogenesis and chondrogenesis, indicating a possible diverse, more complex role in sarcomas than those in carcinomas. Deeper investigation of these factors, together with IGFBPs in sarcomas, may help in elucidating the differences observed in clinical trials.

c. Evaluation of DDRs. DDR1 was reported to act as an oncogene in different tumor types. However, in mesenchymal tumors, the functions of these receptors may be more complex, considering the role that DDRs play in regulating the interactions of mesenchymal cells with collagens and the processes of neural, osteogenic, chondrogenic and myoblast differentiation (Valiathan et al. 2012). A complex functional crosstalk involving IGF1R, IRA, DDR1 and other important signaling molecules like G protein-coupled receptors (GPCRs) has been described to affect gene expression and biological effects in response to IGF1 or IGF2 (Malaguarnera et al. 2015, Avino et al. 2016, Mata et al. 2016, Vella et al. 2017). This multifaceted signaling network has been poorly considered in both the search of predictive biomarkers and the design of new therapeutic strategies in cancers with a dysregulated IGF system; however, a better understanding of these interactions may be clearly relevant. A recently developed compound 7rh is a selective and orally available specific inhibitor of DDR1 enzymatic activity and was found to potently inhibit proliferation, migration and tumorigenicity of cancer cells expressing high levels of DDR1 (Gao et al. 2013) and to improve the chemoresponse when combined with paclitaxel (Aguilera et al. 2017). Therefore, based on the biological affinity between the receptors, combined inhibition of IGF1R or IRA and DDR1 may be considered and investigated as a potential therapeutic strategy, especially in the treatment of sarcomas.

Concluding remarks

The IGF system is clearly involved in regulating tumor growth and, even more importantly, in developing resistance to conventional and targeted drugs. Unfortunately, clinical trials have been dismal, and the field has been largely abandoned. However, an exciting new area of research could help us develop new diagnoses and novel therapeutic approaches. The IGF system is complex, and a more profound level of understanding is required to achieve full exploitation of the therapeutic potentialities of the system. Therefore, clinical and basic researchers should continue to work together to provide new treatments for sarcoma patients.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This work was supported by the Italian Association for Cancer Research (IG2016_18451 to K S) and by the Istituto Ortopedico Rizzoli (Simile contributions to the Rizzoli Institute). Caterina Mancarella was awarded the ‘Guglielmina Lucatello e Gino Mazzega’ fellowship granted by Fondazione Italiana per la Ricerca sul Cancro-FIRC (FIRC project code: 17984), and she was partially supported by the Guido Berlucchi Foundation.

Acknowledgements
The authors thank Cristina Ghinelli for figure editing.

References


Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H & Horneck FJ 2009 Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclonigin picrophodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. *Molecular Cancer Therapeutics* 8 2122–2130. (https://doi.org/10.1158/1535-7163.MCT-09-0115)


Fawzy IO, Hamza MT, Hosny KA, Esmat G & Abdelaziz AI 2016 Abrogating the interplay between IGF2BP2, 3 and 3 and IGFR1 by let-7i arrests hepatocellular carcinoma growth. *Growth Factors* 34 42–50. (https://doi.org/10.3109/098179719.2016.1169532)


Karnieli E, Werner H, Rauscher FJ 3rd, Benjamin LE & LeRoith D 1996 The IGF-I receptor gene promoter is a molecular target for the Ewing’s sarcoma-Wilm’s tumor 1 fusion protein. *Journal of Biological Chemistry* **271**:19304–19309. ([https://doi.org/10.1074/jbc.271.32.19304](https://doi.org/10.1074/jbc.271.32.19304))


Received in final form 19 December 2017
Accepted 22 December 2017